QIAGEN and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography
QIAGEN N.V. and ActiveSight, a protein crystallography service provider, announced that they have entered into a co-marketing agreement related to protein crystallography for drug discovery. The agreement seeks to ease access to protein crystallization reagents and crystallographic services, thereby expanding the opportunities for organizations in need of important structural biology information. Financial terms of the agreement were not disclosed.
According to QIAGEN the companie's line of standardized reagents and kits now enable researchers to use a seamless solution of QIAGEN products from genes all the way through to protein crystals. Crystal analysis and structure resolution can then be performed at ActiveSight, using their equipment for structural determination. ActiveSight also offers protein crystallization set-up using QIAGEN reagents.
Other news from the department business & finance
These products might interest you
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection
Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
